Trial did not prove partial-breast radiation matches whole-breast treatment for breast cancer
- Trial did not prove partial-breast radiation matches whole-breast treatment for breast cancer
- Immunotherapy before surgery was feasible for resectable liver cancer
- Blood immune pattern linked to treatment response in cervical cancer
- Atlas maps immune features linked to skin cancer outcomes
- Tumor protein patterns linked to immunotherapy response in metastatic skin cancer
- Blood test predicted recurrence in head and neck cancer
- TIGIT marker identifies tumor-reactive cells in skin cancer blood
Trial did not prove partial-breast radiation matches whole-breast treatment for breast cancer
In a trial of people with low-risk breast cancer, partial-breast radiation led to cancer returning in 1.0% of patients at five years, compared with 0.8% after whole-breast radiation. The trial did not prove the treatments were equally effective.
“Although formal statistical noninferiority was not demonstrated because the upper confidence limit crossed the margin, the absolute difference was <0.2%.”
Why it matters. People with low-risk breast cancer may have partial-breast radiation as an alternative to treating the whole breast. Results from a large final-stage trial like this decide approvals.
Journal of Clinical Oncology, 17 Nov 2026 · Phase III human clinical trial | 3,309 patients Worth sharing · Share on X · Email a friendImmunotherapy before surgery was feasible for resectable liver cancer
In a phase 1b trial, people with early-stage liver cancer that could be removed received the immunotherapies nivolumab and ipilimumab before surgery. The approach was feasible, but larger trials are needed to confirm its benefit.
“Longitudinal circulating tumour DNA (tumour DNA found in the blood) monitoring could support detection of minimal residual disease (traces of cancer left after treatment) and warrants further prospective validation.”
Why it matters. People with early-stage liver cancer that can be removed may be able to get immunotherapy before surgery. This early safety trial is years from routine use.
The Lancet Oncology, 17 Nov 2026 · Phase I human clinical trialBlood immune pattern linked to treatment response in cervical cancer
In 29 people with advanced cervical cancer, researchers found that a blood immune pattern was linked to better outcomes with the immunotherapies durvalumab and tremelimumab plus vinorelbine chemotherapy. Clinical benefit was 76% in people with more of the pattern, versus 25% in others.
Why it matters. A blood test for this immune pattern may help doctors identify people with cervical cancer more likely to benefit from this treatment. This early safety trial is years from routine use.
Cancer Immunology Research, 17 Nov 2026 · Phase I/II human clinical trialAtlas maps immune features linked to skin cancer outcomes
Researchers analyzed 183 skin cancers using many types of molecular data. Tumor antigens tracked with immune cell presence, while other protein and sugar changes were linked to survival differences.
Why it matters. People with skin cancer may one day get treatment choices guided by tumor features linked to immune response and survival. It studied patient records rather than testing a treatment.
Cancer Discovery, 17 Nov 2026 · Human observational studyTumor protein patterns linked to immunotherapy response in metastatic skin cancer
Researchers studied tumor samples from 164 people with metastatic skin cancer treated with combined immunotherapy. In one study group, the protein-defined group with the highest response rate had 74% respond, compared with 44% in the group with the lowest rate.
“A clinically tractable 127-protein classifier provides a foundation for prospective biomarker-driven combination immunotherapy (treatment that helps the immune system fight cancer) trials.”
Why it matters. People with metastatic skin cancer may one day have treatment choices guided by protein patterns in their tumors. It studied patient records rather than testing a treatment.
Clinical Cancer Research, 17 Nov 2026 · Human observational studyBlood test predicted recurrence in head and neck cancer
Researchers studied people treated with chemoradiotherapy for head and neck cancer. At 12 weeks, the blood test found 69% of recurrences and correctly ruled out recurrence in 100% of people without it.
“Plasma-only methylation-based circulating tumour DNA provided high-specificity (how often the test correctly rules cancer out) prognostic information after definitive CRT in LA-HNSCC, particularly at week 12 and in PET partial-responders. circulating tumour DNA may complement PET/CT for post-treatment risk stratification, but should not be used as a stand-alone test to exclude recurrence.”
Why it matters. People treated for head and neck cancer may get extra information about recurrence risk from a blood test alongside scans. It studied patient records rather than testing a treatment.
Clinical Cancer Research, 17 Nov 2026 · Human observational studyTIGIT marker identifies tumor-reactive cells in skin cancer blood
Researchers studied blood from people with melanoma and found that TIGIT marked immune cells that attacked their tumors, detecting more tumor-reactive cells than PD-1 alone. These cells were more common in people who responded to immune checkpoint treatment.
“Collectively, our data establish TIGIT⁺ CD8⁺ T cells as a potent reservoir of tumor-reactive T cells in peripheral blood and provide a blood-based framework for accelerating TCR discovery and advancing adoptive cell therapy.”
Why it matters. People with skin cancer may benefit from blood tests that help doctors track tumor-reactive immune cells and guide personalized treatment. It studied patient records rather than testing a treatment.
Cancer Immunology Research, 17 Nov 2026 · Human observational studyDeals and stopped trials
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.Terminated · Phase I · Novartis Pharmaceuticals · Reason given: Sponsor decision and not a consequence of any safety concerns.
- Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung CancerTerminated · Phase I · Nerviano Medical Sciences · Reason given: The decision about study closure has not been based on safety profile or clinical data of NMS-03305293 but due to a strategic decision driven by upcoming changes in the treatment landscape.
India
New trials
- 177Lu-ACT319 in FAP Expressing Solid TumorsRadiopharmaceuticals · Phase I/II · 182 people · Actithera INC.
Worth watching
- Blood testing assessed head and neck cancer after treatmentResearchers studied blood tumor DNA testing after chemoradiotherapy in seventy-four people with advanced head and neck cancer. At 12 weeks, the test found 69% of recurrences.
- Genomic testing split risk groups in prostate cancerResearchers compared risk groups with a genomic test in 287,145 people with prostate cancer. High-risk patients with adverse features and a high score had a predicted 5-year spread risk of 17-25% versus 5% with favorable features and a low score.
- Tumor features predicted lasting response to targeted therapy in skin cancerResearchers studied 155 people with metastatic skin cancer who received targeted therapy. Tumor genetic diversity and tumor burden predicted who had no progression for at least 24 months. More immune cells inside tumors were linked to longer survival.
- Molecular Features Underlying Discordance Between Clinical and Genomic Risk Stratification in Localized Prostate Cancer in Over 280, 000 PatientsResearch finding, Clinical Cancer Research, 17 Nov 2026
- Spatial Immune Organization Associates with Response to CD40 Agonism in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: A Phase I TrialPhase I, early-stage human trial, Clinical Cancer Research, 17 Nov 2026
- Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in BRAF-Mutant MelanomaResearch finding, Clinical Cancer Research, 17 Nov 2026